^
    Back
    Association details:
    Biomarker:SMARCA2 overexpression
    Cancer:Ovarian Cancer
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Oncol Lett
    Title:

    Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer

    Excerpt:
    To determine whether these two genes are putatively involved in cisplatin resistance, their mRNA levels in 32 selected patients with different RFS rates after hospital treatment were determined. Based on the RT-qPCR results, patients with shorter RFS (RFS <12 months, no. 01-019) had significantly higher SMARCA2 and CAMK2D levels, compared to those with longer RFS (RFS >12 months, no. 1-13; Fig. 2C).
    DOI:
    10.3892/ol.2018.9109